Heart failure & cardiomyopathies
Novel Therapies to Reduce Rehospitalization Risk in Worsening Heart Failure: Systematic Review and Network Meta-Analysis
Authors' conclusion
Early administration of sodium-glucose co-transporter 2 inhibitors, ARNI, and ferric carboxymaltose for WHF patients significantly reduces rehospitalization risk.
Study context
- Population
- Worsening HF patients, therapies initiated during hospitalization or vulnerable phase
- Participants
- 18,540 patients · 9 RCTs
- Comparison
- Novel HF therapies vs control
- Outcome
- HF rehospitalization
Pooled result
As reported in the abstract
HF hospitalization
Each group vs controlOdds ratio (95% CI)P value
Sotagliflozin
0.50(0.39–0.63)
P < 0.0001ARNI
0.54(0.35–0.83)
P = 0.005Ferric carboxymaltose
0.55(0.44–0.70)
P < 0.0001Empagliflozin
0.56(0.39–0.78)
P = 0.0007Vericiguat 10 mg
0.83(0.74–0.92)
P = 0.0008Finerenone 15 mg
0.59(0.38–0.91)
P = 0.016Original publication
Novel Therapies to Reduce Rehospitalization Risk in Worsening Heart Failure: Systematic Review and Network Meta-Analysis. JACC Adv. Published 17 December 2024. doi:10.
Summarised from the published abstract; every number is checked against it